Different studies showed that tumour cells could express on their surface PD‐L1, suggesting a potential role of this protein in reducing the anti‐cancer immune response.19 These findings improved the research in anti‐cancer drug development, which could interact with the PD‐1/PD‐L1 pathway. This evidence concerns the gene PDCD1 and neoplasm.